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Abstract
Background: South Africa remains the country with the greatest burden of HIV-infected individuals and the
second highest estimated TB incidence per capita worldwide. Within South Africa, KwaZulu-Natal has one of the
highest rates of TB incidence and an emerging epidemic of drug-resistant tuberculosis.
Methods: Review of records of consecutive HIV-infected people initiated onto ART between 1
st January 2005 and
31
st March 2006. Patients were screened for TB at initiation and incident episodes recorded. CD4 counts, viral loads
and follow-up status were recorded; data was censored on 5th August 2008. Geographic cluster analysis was
performed using spatial scanning.
Results: 801 patients were initiated. TB prevalence was 25.3%, associated with lower CD4 (AHR 2.61 p = 0.01 for
CD4 <50 cells/μl) and prior TB (AHR 1.58 p = 0.02). Incidence was 6.89 per 100 person-years from 81 cases over
1175 person-years analysis time and was highest in the first 3 months after ART initiation; associated with male sex
and higher log HIV RNA. Prevalent and incident TB were significantly associated with mortality (OR 1.81 p = 0.01
and 2.02 p = 0.01 respectively). Incident TB was associated with a non-significant trend towards viral load >25
copies/ml (OR 1.75 p = 0.11). A low-risk cluster for incident TB was identified for patients living near the local
hospital in the geospatial analysis.
Conclusion: There is a large burden of TB in this population. Rate of incident TB stabilises at a rate higher than
that of the overall population. These data highlight the need for greater research on strategies for active case
finding in rural settings and the need to focus on strengthening primary health care.
Background
South Africa remains the country with the greatest bur-
den of HIV positive individuals [1] and the second high-
est estimated TB incidence per capita worldwide [2].
Within South Africa, the province of KwaZulu-Natal has
the greatest number of HIV positive individuals (an esti-
mated 1.2 million people), with a sustained high inci-
dence of new adult HIV infections [3]. TB notification
rates are high with 1094 cases per 100,000 population,
compared to a national incidence of 739.6 [4] and an
emerging epidemic of drug resistant TB, which has
received international attention [5]. Drug resistant TB
has been identified as a major threat to the success of
antiretroviral roll-out [6] and in areas where HIV and
TB prevalence are high, both will require locally tailored
interventions far beyond any current efforts. To add to
limited data from urban and peri-urban settings [7,8],
we set out to explore the burden and impact of TB in a
cohort of patients initiating ART in rural KwaZulu-
Natal. We further used novel geospatial clustering analy-
sis to define areas where incident TB rates are higher or
lower than might be expected; such areas could be used
for targeted behavioural analysis, to aid our understand-
ing of the TB epidemic in HIV infected individuals, and
measure the impact of interventions to curb it.
Methods
The study was carried out within the public sector ART
programme of Hlabisa sub-district, Umkhanyakude,
KwaZulu-Natal. The sub-district is predominantly rural
with a population of approximately 228,000 people [9]. * Correspondence: catherine.houlihan@doctors.org.uk
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Care Programme started in 2004 and is run in partner-
ship with the Africa Centre for Health and Population
Studies, with funding from PEPFAR http://www.africa-
centre.ac.za. HIV and TB services are decentralised to
primary care, offering initiation of ART at 15 clinics by
2006. In 2004, the HIV prevalence was high at 22%
overall, and peaked at 51% in females in 25-29 year age
group [10]. Standard South African DoH approved ART
regimens are used [11] (stavudine and lamivudine with
either efavirenz or nevirapine in the initial regimen),
with standard criteria for ART eligibility (stage 4 disease
or CD4 <200 cells/μL). Once on treatment, patients are
advised to return for CD4 and HIV RNA viral load test-
ing six monthly and medication collection monthly.
During the preparation to start ART, patients were
screened for TB, using symptom screen and AFB smear.
In 2005, chest X-ray (CXR) was available only in the
hospital, from early 2007, CXR was also available free in
the local town. TB diagnosis and treatment were accord-
ing to the National TB Control Programme Guidelines
[12]. Sputum culture was not routinely available.
CD4 count, HIV RNA viral load, WHO clinical stage
at baseline, date of initiation, ART regimen, TB treat-
ment (at ART initiation and subsequently) and outcome
(loss to follow-up, transfer out and death) were routinely
collected in a database. Patient records were reviewed by
a clinician to independently validate the data and record
additional information, therefore only those with files
available in the clinics were included (clinics store files
of those lost to follow-up and deceased).
Ethics approval was granted by University of Kwa-
Zulu-Natal Biomedical Research Ethics board (Reference
BE066/07) and the Research Office of the KwaZulu-
Natal Department of Health.
Statistical Analysis
Multivariate logistic regression analysis was used to
examine baseline factors independently associated with
prevalent TB. WHO stage at initiation was dropped in
both univariate and multivariate analysis due to colli-
nearity as all people with prevalent TB were WHO stage
3 or 4 by definition [11]. Incident rates of TB were cal-
culated using Kaplan-Meier survival analysis. Cox pro-
portional hazards regression modelling was used to
evaluate associations with incident TB; person-time was
censored on 5
th August 2008. Incidence rates were cal-
culated as the total number of newly diagnosed TB
cases divided by the time at risk of TB and also as the
number of new TB cases divided by the person-time
contributed before the first TB episode. Analysis time
was censored at the time of death, last clinic visit (for
lost to follow-up) or date of incident TB [13]. Indepen-
dent variables were included in multivariate models if
univariably associated with outcome at 15% significance
level or if they affected associations involving other cov-
ariates. Patients with prevalent and/or incident TB were
compared with those without to assess the effect of TB
on mortality and virological failure. All statistical ana-
lyses were conducted using STATA version 10.0 (SAS
institute, Cary, North Carolina, USA).
Spatial Clustering analysis
A spatial scan was used to explore geographical differ-
ences in TB incidence across the sub-district. The Africa
Centre maintains a GIS database of all local areas (a Zulu
neighbourhood with a median population of about 400
people) in the sub-district. Patients without prevalent TB,
residing within the sub-district and with a valid address,
were carefully geo-coded to the centroid of their corre-
sponding local area using our geographic database. We
then applied a Kulldorff spatial scan statistic (implemen-
ted within the SaTScan spatial cluster detection pro-
gramme [14]) to identify clusters of incident TB
infections (either high or low numbers of infections) at a
local area level using an exponential survival model [15].
A spatial scan statistic is a cluster detection test that is
able to both detect the location of clusters and evaluate
their statistical significance without problems associated
with multiple testing. The statistical theory behind the
spatial scan statistic is described in detail elsewhere [16].
The spatial scan statistic imposes a circular window
on a map and it allows the centre of the circle to move
across the study region. For any given position of the
centre, the radius of the circle changes continuously so
that it can take any value from zero up to a specified
maximum value. The statistic evaluates the incidence of
TB infection within a circle relative to expectation
(based on the mean TB incidence for patients used in
this analysis). The circle with the maximum likelihood is
defined as the most likely cluster, implying that it is
least likely to have occurred by chance. The p-value of
the statistic is obtained through Monte Carlo hypothesis
testing (9,999 iterations), where the null hypothesis of
no clustering is rejected if the simulated p-value is <
0.05.
Definitions
An episode of TB included any individual who started
TB treatment irrespective of smear or culture positivity,
similarly it encompassed any notified case of TB in the
cohort. Prior TB was defined as any recorded episode of
TB treatment, complete by time of ART initiation. Pre-
valent TB was defined as patients receiving TB treat-
ment at ART initiation, including those already on
treatment at programme entry and those diagnosed by
pre-ART screening. Incident TB was any new episode of
TB treatment after ART initiation.
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copies/ml, this definition was used not to indicate clini-
cal treatment failure but to indicate those who have
unsuppressed viral replication for this study. Lost to fol-
low-up was defined as no clinic attendance on two con-
secutive occasions (2 months) and limited tracking of
those defaulting treatment was available with telephone
calls. No information was available on outcomes from
the separate DoH TB programme.
Results
801 adults aged 16 or older started ART between the 1
st
January 2005 and 31
st March 2006 (Figure 1) and had
files for review (missing files n = 83). Those transferred
in from another government programme were included.
Transfers from GP or non-governmental programmes (n
= 8) were included for TB prevalence analysis but
removed before incidence and survival analysis because
of unknown previous ART regimens. There were 258
missing baseline viral loads and 25 missing baseline
CD4 counts.
Median age at treatment initiation was 36 years (IQR
31-44), 561 (69.9%) were female. 50.6% (n = 405) were
WHO stage 3, 9.0% (n = 72) stage 4. WHO staging was
not recorded for 98 (12.2%). Median CD4 count was
119.5 cells/μl (IQR 60-175) and median log10 HIV RNA
4.76 copies/ml (IQR 4.15-5.26).
Prevalent TB
784 (of 801) had a complete TB record at ART initia-
tion; 198 of whom (25.3%) had prevalent TB (95%CI
22.3-28.6%). Of those with prevalent TB, 84 had also
had prior TB (42.9%). Prevalent TB was associated with
CD4 below 50 cells/μl, higher baseline Log10 HIV RNA
and prior TB (Table 1). No data was available on
method of diagnosis in prevalent TB cases.
Outcomes
The median follow-up time was 2.18 years (range 0-
3.50). 646 (77%) were still active at the time of data cen-
soring, 104 (13.0%) had died and 51 (6.4%) were lost to
follow-up or transferred out.
Of the 46 lost to follow-up, median time to loss was
522 person days (IQR 223-706), median baseline CD4
137 cells/μl (IQR 60-162) and log10 HIV RNA 4.59
copies/ml (IQR 4.23-5.26), 37 had no prevalent or inci-
dent TB, 9 had prevalent and 6 incident TB.
Figure 1 Flow diagram illustrating patients used in the analysis.
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583 observations were used for analysis; 198 with preva-
lent TB were excluded and 20 others had missing end
date leaving 81 episodes of TB analysed over 1175 years
analysis time. Overall incidence was 6.89 per 100 person
years, highest in the first three months at 17.4 per 100
person years (Table 2), and 5.33 per 100 person years
after 2 years. In multivariate analysis young age, male
sex and higher log10 HIV RNA (Table 3) were associated
with incident TB in the first three months. After three
months, advanced HIV stage (3 or 4) was significantly
associated with incident TB. Prior TB was not indepen-
dently associated with incident TB.
Of the above 81 individuals who developed TB whilst
on ART, 14 (17.3%) were smear positive and 1 culture
positive, 17 (20.1%) did not have the method of diagno-
sis recorded, 30 (37.0%) were diagnosed on CXR. 14
were diagnosed on clinical suspicion (17.3%), 1 on CT
findings (1.2%), 2 on lumbar puncture findings (2.5%)
and 2 on ultrasound findings.
Spatial Clustering of Incident TB
403 individuals (821 person-years of observation) with-
out prevalent TB and with a valid address were geo-
coded to 79 local areas. No clusters of unusually high
TB incidence were detected anywhere in the sub-dis-
trict. A significantly low-risk cluster of radius 4.2 km
was detected in communities around Hlabisa Hospital
(Figure 2). The overwhelming majority (95%) of person-
years of observation in this cluster were contributed by
patients geo-coded to the area immediately surrounding
the hospital. In this cluster, only six new TB cases were
observed over 151.9 person-years of observation -
approximately one quarter of the expected incident
cases (Relative Risk = 0.28, log likelihood ratio = 11.0, p
= 0.019).
Table 1 Description of baseline characteristics stratified by prevalent TB and univariate and multivariate analysis of
factors associated with prevalent TB.
Variable Prevalent TB n(%) No Prevalent TB n(%) Unadjusted OR (95%CI) Adjusted OR (95%CI)
Sex
Female 136 (68.7) 413 (70.5) REF
Male 62 (31.3) 172 (29.5) 1.09 (0.77-1.54)
Age (yrs) 35 (IQR 30-42) 37 (IQR 31-44) 0.98 (0.97-1.00) 0.99 (0.97-1.01)
Transfer in
No 192 (97.0) 563 (96.1) REF
Yes 6 (3.0) 23 (3.9) 0.76 (0.31-1.91)
CD4 at initiation 88 [IQR 30-153] 129 [IQR 71-179]
>200 REF REF
50-200 1.30 (0.80-2.10) 1.03 (0.58-1.86)
<50 3.22 (1.88-5.51) 2.61 (1.36-5.03)
Baseline RNA VL (log10) 4.91 4.70 1.26 (1.01-1.58) 1.23(0.99-1.54)
Prior TB
No 113 (57.1) 387 (66.0) REF REF
Yes 85 (42.9) 199 (34.0) 1.46 (1.05-2.03) 1.58 (1.06-2.36)
WHO Stage
1o r2 N/A 214 (36.5) N/A N/A
3o r4 198 (100) 282 (48.1) N/A N/A
Unknown N/A 90 (15.4) N/A N/A
Table 2 Baseline characteristics associated with incident TB stratified by time since ART initiation
Time since ART initiation (months) Person time (years) TB cases TB incidence rate (per 100 person years) 95% confidence interval
0-3 138.00 24 17.39 11.65-25.94
3-6 130.65 11 8.42 4.66-15.20
6-9 126.44 7 5.53 2.64-11.61
9-12 122.67 7 5.71 2.72-11.97
12-18 236.84 13 5.48 3.18-9.45
18-24 214.20 8 3.73 1.87-7.47
>24 206.34 11 5.33 2.95-9.63
Overall 1175.17 81 6.89 5.54-8.57
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Total follow-up time was 1706 person years with an
overall mortality of 6.3 per 100 person years (95% CI
5.2-7.6). 13 people had to be excluded from the out-
comes analysis because of missing end date (i.e. no date
of death or date of last follow-up available).
Mortality rate was significantly higher in those with
prevalent and incident TB than in those without; 9.1 per
100 person years (95% CI 6.6-12.6) versus 5.3 (95% CI
4.2-6.8) and 9.2 (95% CI 5.6-15.0) versus 4.4 (95% CI
3.3-5.8) respectively. Similarly, mortality was 21.2% in
incident TB cases, 11.8% in those without; 19% in preva-
lent TB, and 11.5% in those without (chi-2 p-value of
0.007, p = 0.008). Hazard risk for mortality in those
with prevalent TB was 10 times higher in the first six
months after initiation than later (Figure 3a), and was
also higher in those with incident TB compared to those
without incident TB (Figure 3b)
Virological Outcome
Virological failure occurred in 71 (12.8%) of 555 people
with follow-up viral loads. Median time from initiation
to last viral load was 900 days (range 349-1336). 12 pre-
valent TB cases (9.4% of the 128 with prevalent TB) had
virological failure versus 59 (14.4% of 411 without pre-
valent TB) p = 0.15. Conversely, virological failure was
more common in incident TB cases than those without
(12/63; 19.1% versus 58/490; 11.8%(p = 0.11)).
Discussion
The extremely high TB prevalence in our study demon-
strate that South Africa’s dual HIV and TB challenge is
not confined to urban settings; this rural cohort had a
TB prevalence of 25.3%, similar to urban South Africa
[8,17] and higher than figures reported elsewhere in
sub-Saharan Africa [7,18,19].
HIV associated immunosuppression is known to
increase the development of active TB in those latently
infected and increase susceptibility to new TB infection
[20,21]. We show that people with a CD4 count of less
than 50 cells/μl prior to ART initiation were more likely
to have prevalent TB, which is consistent with previous
findings [8,19].
The incidence of TB following ART initiation was
similar to that observed within an urban community in
Cape Town [8]. Despite similar cohort characteristics,
the incidence within the first 3 months in our study,
whilst within confidence intervals, is slightly lower. In
that study, sputum culture was part of the work-up,
whilst in our setting culture was performed infrequently.
Given that much of the TB is pulmonary, this again
highlights the need for more active and aggressive diag-
nosis within a rural setting.
The high incidence of TB in the initial three months
of ART compared with later may reflect an immune
reconstitution inflammatory syndrome (IRIS) to TB
infection which was present, yet undiagnosed at the
time of ART initiation; this phenomenon has been
termed unmasking tuberculosis-associated IRIS [22]. In
this analysis, incidence refers to the incidence of diagno-
sis of disease rather than disease per se. The quoted fig-
ures for prevalence are therefore of prevalent diagnosed
disease and the actual prevalence of disease might be
higher. Incident calculations are not affected by high
Table 3 Changes in TB incidence rate during antiretroviral therapy among 583 patients initiating treatment.
Initial 3 months (n = 583
individuals)
After 3 months (n = 559
individuals)
Variable Unadjusted Hazard Ratio (95%
CI)
Adjusted Hazard Ratio
(95% CI)
Unadjusted Hazard Ratio (95%
CI)
Adjusted Hazard Ratio
(95% CI)
Age (years) 0.99 (0.95-1.04) 0.87 (0.79-0.96) 0.98 (0.95-1.10) N/S
Sex;
Female REF REF
Male 4.17 (1.83-.54) 9.55 (2.35-38.78) 0.59 (0.30-1.16) 0.55 (0.27-1.10)
Log10 HIV
RNA
1.85 (0.86-3.97) 2.69 (1.11-6.51) 0.83 (0.59-1.13) N/S
Transfer in 0.99 (0.13-7.30) N/S 0.38 (0.05-2.78) N/S
Log10 CD4 1.35 (0.78-2.40) 2.02 (0.58-4.76) 0.83 (0.65-1.07) 0.87(0.67-1.13)
Prior TB;
No REF REF
Yes 1.42 (0.63-3.20) 1.16 (0.33-4.03) 1.77 (1.04-2.98) 1.32 (0.73-2.38)
WHO stage
1o r2 REF REF
3o r4 2.33 (0.92-5.92) N/S 2.11 (1.15-3.87) 1.94 (0.99-3.38)
Unknown 0.40 (0.05-3.32) N/S 1.27 (0.52-3.12) 1.43 (0.58-3.56)
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Page 5 of 9Figure 2 Map of Hlabisa sub-district illustrating clinics and 403 patients with no prevalent TB at baseline. The low-risk incident cluster
around Hlabisa Hospital of radius = 4.2 km is shown.
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Page 6 of 9numbers of new TB diagnosis in the first two weeks,
however, as this was only recorded in 4 cases; removal
of these 4 from incidence calculations does not affect
the final rate. Obviously it is impossible to comment on
deceased or lost to follow-up cases.
The association between previous, prevalent and inci-
dent TB is complex and the subject of some debate
[8,23] and conflicting evidence [8,19,24]. Our study is
limited in the detail available about previous treatment
and the number of follow-up CD4 results available; and
therefore we were unable to confirm an association
between higher CD4 attainment during ART and
reduced TB incidence. However, we did find that pre-
vious TB was independently associated with prevalent
TB at initiation, for which there are a number of possi-
ble explanations. In areas of high transmission, for
example particular households or workplaces, re-infec-
tion may be common, particularly amongst the immu-
nologically vulnerable. High re-infection rates may also
be explained by nosocomial spread of TB within hospi-
tals and clinics [25]. Delayed diagnoses coupled with
lack of infection control adds to the increased risk of re-
infection. Previous poor treatment adherence is another
potential explanation, as relapse of partially treated dis-
ease as immunodeficiency advances could account for
retreatment. In the absence of routine culture based
testing it is not possible to tell whether drug resistance
TB could account for the significant number of indivi-
duals requiring retreatment, but community rates of
drug resistance are high with 40-55% [26] of individuals
who gave culture specimens on retreatment showing
evidence of some drug resistance, and 27% retreatment
cases identified as MDR [27]. Drug resistant TB in the
HIV setting is of particular concern for the control of
both epidemics [6].
Separately analysing incidence in the initial three
months and thereafter allows us to illustrate the factors
strongly associated with incident TB. Male sex and
younger age were not risk factors in the cohorts in Cape
Town, Uganda and the Ivory Coast [8,19,24] but were in
the ART-LINC cohort [28] and male sex, lower CD4
and lower BMI were associated with incident TB in
Johannesburg [29]. Male gender has been historically
linked to increased TB incidence [30] but in our study
was associated with TB incidence only in the first three
months post ART initiation. This may be attributable to
illness behaviour; symptom denial at the time of presen-
tation for ART initiation may be more common in men
and therefore higher rates of immune reconstitution TB
may be expected in men. Male sex in previous South
African studies has been associated with increased delay
in diagnosis of TB [31]. Work related or social beha-
vioural exposure such as travel in minibus taxis may be
more common in men, and these may be areas of target
for active case finding activities for both TB and HIV, it
would be expected however, that this higher rate in men
continue after three months which it does not in this
study. After the initial three months, we found that only
advanced HIV stage was significantly associated with
incident TB, a finding which supports other evidence
that more advanced disease at initiation is associated
with increased risk of TB disease [28].
The high TB incidence and high mortality in the first
three months after initiation of ART necessitates
improved active case finding through, amongst other
things, optimised screening practices. The high mortality
from TB in HIV infected individuals has been clearly
illustrated in South Africa [32]. The challenge can best
be addressed by the integration of TB and HIV services
[33], especially in the most rural and under-resourced
areas. Further, there is potential for investigating the use
of targeted chemoprophylaxis with isoniazid possibly
both pre and post ART initiation; although there
remains significant concern about this approach in an
area of high levels of TB drug resistance [34].
Previous studies have shown similar virological out-
comes in HIV patients on ART taking concurrent TB
treatment and those not taking TB treatment [8,35].
However, these were urban patients and follow up was
less than two years. We have illustrated a non-signifi-
cant trend towards detectable viral load in cases with
incident TB. A longer period of follow-up might reveal
significance. What is clear from our data is the strong
association between prevalent and incident TB and mor-
tality. This illustrates an opportunity to select groups in
need of increased support and monitoring and advocates
for the prevention of late presentation with illness on,
and before ART.
Interestingly, the incidence of new TB cases was not
geographically uniform across the sub-district and a
cluster of unusually low TB incidence was detected sur-
rounding the district hospital. These communities close
to the hospital have easy access to diagnostic investiga-
t i o n ss u c ha sc h e s tx - r a y s ,a n dw e r ew i t h i ne a s i e s t
access of the first ART services in 2004/5. Both of these
reasons may have contributed to earlier ART initiation
in comparison to the rest of the sub-district. This in
turn may have resulted in a reduced risk of incident TB,
and earlier access to TB diagnosis and treatment leading
to a reduction in the community’s overall burden of TB
disease.
However, 40% of patients geo-coded to the low-risk
cluster reported living in the Hlabisa tribal area but only
supplied a postal (and not a physical) address. It is
therefore at least theoretically possible that a social
rather than a geographical clustering pattern is being
detected. This explanation is improbable, however, given
the high population concentration in this area and the
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where their post is collected. The use of geospatial tech-
niques for analysing clustering of TB cases will aid
understanding of the TB epidemic in rural sub-Saharan
Africa (SSA), similar to the way in which mapping of
HIV cases has highlighted not only areas where high
transmission is occurring (along major transit routes
[36]) but also the targeting of areas where infection con-
trol interventions will be most effective. This analysis is
particularly important in HIV and TB co-infection
which remains a leading killer in SSA.
Our study has several limitations. The original pur-
pose of this programme is service and not research and
care is largely provided by nurses and counsellors. It is
therefore possible that the information recorded does
not give a full picture of TB incidence. Further, in this
sub-district of 2280,000 people, where over 3,500 TB
cases are diagnosed annually, and as many as 80% of
pulmonary cases are smear negative (Tom Heller, perso-
nal communication March 2009), the possibility of over-
diagnosing TB on clinical grounds cannot be dismissed.
We are restricted by lack of information on the cause of
mortality or the status of lost to follow-up patients. It is
possible that several of our deceased patients had inci-
dent TB, and some of the defaulted patients may have
been started on TB treatment.
In our study, the absence of data from the era prior to
ART hinders drawing conclusions about the potential
impact of ART on the risk of developing TB. Studies in
urban South Africa suggest a reduced incidence of TB
for HIV infected people taking ART before and after
national roll-out [8,37] and some have suggested that
the reduction in TB incidence in high and low-income
countries after HAART is as high as 70-90% [38]. How-
ever there is lack of evidence for rural populations
which face different challenges. The risk of TB whilst on
ART during long term follow-up becomes stable in our
setting at a rate six times higher than the overall TB
incidence in KwaZulu-Natal [4] which supports sugges-
t i o n st h a tA R Ta l o n ew i l ln o tb eaf u l l ye f f e c t i v eT B
control strategy for several reasons, including the lack of
restoration of MTB immune response on ART to that
of an HIV negative person coupled with prolonged life-
span after ART [38].
Conclusion
To impact on the high rates of both prevalent and inci-
dent TB in this and other resource poor settings, and to
prevent associated high mortality and morbidity, a com-
bination of strategies must be used. This should include
preventing late entry into HIV care and onto ART,
infection control measures around TB, targeted
enhanced screening and enhanced adherence support
for those on both TB and HIV treatment. The data
presented here and reduced incidence of TB around the
hospital also suggests that more emphasis should be
placed on strengthening services away from the hospital,
either in primary care or at a household level. In order
for these strategies to be as sustainable and as effective
as possible, they will need to be integrated with each
other and into existing primary health care for other
chronic diseases. Further understanding of the TB epi-
demic in HIV infected individuals will be greatly
enhanced by the use of geospatial analysis of cases. The
development of TB resistance remains an important fac-
tor driving the ongoing TB epidemic, a worse tragedy
will be if TB further encourages HIV resistance and pre-
vents ART roll-out from impacting on the high mortal-
ity rates.
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